VXRT - Vaxart, Inc.
| Previous Close | 0.5300 |
| Open | 0.5200 |
| Bid | 0.5102 x 800 |
| Ask | 0.5400 x 1100 |
| Day's Range | 0.4488 - 0.5201 |
| 52 Week Range | 0.2500 - 5.0000 |
| Volume | 2,465,262 |
| Avg. Volume | 876,857 |
| Market Cap | 32.589M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5100 |
| Earnings Date | Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 08, 2012 |
| 1y Target Est | 4.00 |
- American City Business Journals
Life science companies make first moves to attack deadly coronavirus
At least three Bay Area companies say they could jumpstart programs to find treatments or vaccines for the respiratory infection that has swept part of China and crept into two people in the United States.
- GlobeNewswire
Results from Influenza Challenge Study Published in Lancet Infectious Diseases
Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that the results from its H1 influenza oral tablet vaccine challenge study were published in the Lancet Infectious Diseases, January 21, 2020 and currently available at doi.org/10.1016/S1473-3099(19)30584-5. Topline results had been reported previously. The study demonstrated a single dose with the Vaxart oral tablet H1 influenza vaccine was well tolerated and provided statistically significant protection against H1 influenza infection in the human challenge model.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Vaxart, Inc. (VXRT)
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees in 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
- GlobeNewswire
Vaxart Announces Third Quarter 2019 Financial Results and Provides Corporate Update
- $9 million Underwritten Public Offering Closed - - Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study - SOUTH SAN FRANCISCO, Calif.,.
- GlobeNewswire
Vaxart Hosting Key Opinion Leader Meeting on the Health Economics of Norovirus Disease
Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it will host a key opinion leader (KOL) meeting on the health economics of norovirus disease on Thursday, November 14th in New York City. The meeting will feature a presentation by KOL Bruce Y. Lee, M.D., City University of New York, reviewing the current economic impact and unmet medical need for treating patients with norovirus infection. Dr. Lee will be available to answer questions at the conclusion of the event.
- GlobeNewswire
Vaxart, Inc. Announces Changes to its Board of Directors
Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that four new members have been appointed to the Board of Directors effective immediately. Steven Boyd, Keith Maher, M.D., Todd Davis and Bob Yedid were all unanimously approved as directors.
- GuruFocus.com
Largest Insider Trades of the Week
Mark Zuckerberg sheds shares of Facebook Continue reading...
- GlobeNewswire
Vaxart to Present Clinical Data From its Norovirus Phase 1b Study at Three Global Healthcare Conferences in October 2019
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by.
- GlobeNewswire
Vaxart Announces Pricing of $8 Million Underwritten Public Offering
Vaxart, Inc. (VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public offering of 26,666,667 shares of common stock (which includes pre-funded warrants to purchase up to an aggregate of 4,100,000 shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 26,666,667 shares of common stock. Each share of common stock and, as applicable, pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.30.
- GlobeNewswire
Vaxart’s Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study
Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced positive topline results from the randomized, double-blind, placebo-controlled Phase 1b safety, immunogenicity and interference study with its oral tableted bivalent norovirus vaccine in healthy adults. The study met all primary endpoints for safety and demonstrated robust immunogenicity, with 78% - 93% of subjects responding by eliciting IgA antibody secreting cells (ASC), a key marker for mucosal immunity and a potential correlate of protection for norovirus disease.
- Simply Wall St.
Do Institutions Own Vaxart, Inc. (NASDAQ:VXRT) Shares?
If you want to know who really controls Vaxart, Inc. (NASDAQ:VXRT), then you'll have to look at the makeup of its...
- Zacks
Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)
Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.
- Zacks
Endo International Files BLA for Label Expansion of Xiaflex
Endo International (ENDP) files BLA for the additional indication of Xiaflex [collagenase clostridium histolyticum (CCH)] for the treatment of cellulite in the buttocks.
- Simply Wall St.
Those Who Purchased Vaxart (NASDAQ:VXRT) Shares A Year Ago Have A 77% Loss To Show For It
As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...
- Business Wire
Vaxart to Present at ASM Microbe 2019
Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., senior scientist at Vaxart, will present preclinical results of its oral Respiratory Syncytial Virus vaccine in a poster presentation at the American Society of Microbiology 2019, taking place from June 20-24, ...
- Business Wire
New Publication in Vaccine Highlights Preclinical Results of Vaxart’s Mucosal Chikungunya Vaccine
Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the publication of the comprehensive results from a preclinical trial of its chikungunya vaccine in the peer reviewed journal, Vaccine. The article, titled “An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling,” details the results from a study using Vaxart’s chikungunya vaccine candidate in a preclinical efficacy model. “These preclinical results demonstrate that our vaccine candidate induced significant neutralizing antibodies against chikungunya virus as well as protective efficacy against virus-induced pathologic changes,” said Sean Tucker, Ph.D., founder and chief scientific officer of Vaxart.
- Business Wire
Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update
- $13 million raised in 1H19 -
- Simply Wall St.
Have Insiders Been Buying Vaxart, Inc. (NASDAQ:VXRT) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We often see insiders buying up shares in companies that perform well over the long term. The flip side...
- Business Wire
Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it has started dosing subjects in the randomized cohort of the Phase 1b bivalent norovirus vaccine clinical trial. “We are delighted to start the randomized portion of the bivalent norovirus phase 1b trial,” said David Taylor, M.D., chief medical officer of Vaxart. Norovirus is the leading cause of foodborne illness in the United States and causes significant morbidity and mortality in older adults and the very young.
- Business Wire
Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases
Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scientist at Vaxart, will present preclinical data in a poster presentation at the 29th European Congress of Clinical Microbiology and Infectious Diseases showing that Vaxart’s oral quadrivalent influenza vaccine conferred 100% protection against a lethal H5N1 avian influenza challenge in ferrets.
- Business Wire
Vaxart Announces Pricing of Underwritten Public Offering
Vaxart, Inc. (VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public offering of 9,090,010 shares of common stock (which includes pre-funded warrants to purchase up to an aggregate of 8,165,455 shares of common stock in lieu thereof), and common warrants to purchase up to an aggregate of 9,090,010 shares of common stock. Each share of common stock and, as applicable, pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at an effective price to the public of $1.10 per share and accompanying common warrant. Each common warrant will have an exercise price of $1.10 per share, be exercisable immediately and will expire five years from the date of issuance.
- Business Wire
Vaxart to Present at Global Medical Meetings in April
Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced participation in two upcoming global medical meetings in April.
